Efficacy of Zelnate® DNA Immunostimulant for BRD control1

As measured by reduction in lung lesions


Evaluate the efficacy of Zelnate for BRD control as measured by reduction in lung lesions.

Study Procedures

In this study, healthy steers 3-4 months of age were randomly allocated into two groups (n=32 per group). On Day 0, animals were challenged via intratracheal route (Mannheimia haemolytica) and received at the same time an intramuscular injection of either Zelnate or a placebo treatment.

Zelnate group: Zelnate (2 mL)

Control group: Placebo (2 mL)

Clinical examination and lung lesion scoring was performed on dead animals on Days 1-4, and lung lesion scoring of surviving animals was performed on Day 5.


The lung lesion scores in the chart reflect those observed on Day 5 post-challenge.

Zelnate vs. Control: Average Lung Lesions


*Statistically significant reduction (P < 0.05)

Zelnate, as a stand-alone therapy, has been shown to significantly reduce lung lesion scores associated with BRD when administered in the face of disease challenge.

Why do lung lesions matter?

Feedlot cattle with lung lesions at slaughter (due to prior bouts of BRD) display inferior average daily gain (ADG) compared to cattle without lung lesions. On average, cattle with lung lesions are valued $77.07 less per head compared to pen-mates without lung lesions. Recent research suggests that the loss of ADG among cattle with lung lesions was the primary driver of an economic value difference between cattle with and without lung lesions.2

See the full technical report pdf

1Data on file. Bayer HealthCare Animal Health.

2Nickell J. (2014). A stochastic model designed to estimate discrepancies in the relative economic value between cattle with and without lung lesions in U.S. feedlot production systems. Poster presented at: BRD Symposium, July 30-31, 2014.

Was this content helpful?